Oslo, Norway, 1 December 2020: Reference is made to the stock exchange release
by Photocure ASA ("Photocure" or the "Company") published on 30 November 2020
regarding exercise of share options.

The price for option shares sold by primary insiders have been determined at a
price of NOK 79.0128 per share.

The primary insiders having exercised options have purchased shares in Photocure
at a price per share of NOK 79.0128 as follows:

  · Erik Dahl, CFO, has purchased 7,189 shares. Following completion of the
purchase, Erik Dahl holds, directly or indirectly, 20,222 shares, 35,000
conditional share options and 40,000 share options in the Company.
  · Grete Hogstad, VP Strategic Marketing, has purchased 5,032 shares. Following
completion of the purchase, Grete Hogstad holds, directly or indirectly, 26,876
shares, 25,000 conditional share options and 25,000 share options in the
Company.
  · Gry Stensrud, VP Technical Development and Operation, has purchased 12,553
shares. Following completion of the purchase, Gry Stensrud holds, directly or
indirectly, 22,442 shares, 25,000 conditional share options and 18,750 share
options in the Company.

For further information, please contact:

Photocure CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to sections
5-12 and 4-2 of the Norwegian Securities Trading Act.